Eli Lilly raises revenue outlook as weight-loss drug demand grows
๐ Eli Lilly reported Q3 revenue of $24.4 billion, up 39% year over year. Mounjaro and Zepbound remained the main drivers, contributing nearly 66% of total sales.
๐ The company raised its 2026 revenue forecast to $91โ92 billion from $85โ87 billion. The $5.5 billion midpoint increase reflects expectations for continued volume growth.
โ๏ธ Global sales volume rose 53%, while realized prices fell 15%. Higher volume is offsetting pricing pressure and supporting revenue growth.
๐งพ Adjusted earnings guidance edged lower due to acquired research charges. This decline should be viewed separately from underlying business growth.
๐ The key issue is whether volume growth can keep offsetting lower prices. That balance will help determine how sustainable Lillyโs revenue momentum remains.
#EliLilly $LLYB
๐ Eli Lilly reported Q3 revenue of $24.4 billion, up 39% year over year. Mounjaro and Zepbound remained the main drivers, contributing nearly 66% of total sales.
๐ The company raised its 2026 revenue forecast to $91โ92 billion from $85โ87 billion. The $5.5 billion midpoint increase reflects expectations for continued volume growth.
โ๏ธ Global sales volume rose 53%, while realized prices fell 15%. Higher volume is offsetting pricing pressure and supporting revenue growth.
๐งพ Adjusted earnings guidance edged lower due to acquired research charges. This decline should be viewed separately from underlying business growth.
๐ The key issue is whether volume growth can keep offsetting lower prices. That balance will help determine how sustainable Lillyโs revenue momentum remains.
#EliLilly $LLYB
